Sangamo BioSciences Announces Presentation At The 2014 JMP Securities
RICHMOND, Calif., June 17, 2014
RICHMOND, Calif., June 17, 2014 /PRNewswire/ --Sangamo BioSciences, Inc.
(NASDAQ: SGMO) announced today that Philip Gregory, D.Phil., Sangamo's senior
vice president of research and CSO, will provide an update on the progress of
Sangamo's ZFP Therapeutic^® development programs and an overview of the
company's business strategy at 3:30 pm ET on Tuesday, June 24, 2014, at the
9th Annual JMP Securities Healthcare Conference. The conference is being held
in New York.
Sangamo BioSciences, Inc.
The presentation will be webcast live and may be accessed via a link on the
Sangamo BioSciences website in the Investor Relations section under Events and
Presentations. The presentation will be archived on the Sangamo website for
two weeks after the event.
Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures™for
monogenic and infectious diseases by deploying its novel DNA-binding protein
technology platform in therapeutic gene regulation and genome editing. The
Company has ongoing Phase 2 clinical trials to evaluate the safety and
efficacy of a novel ZFP Therapeutic^® for the treatment of HIV/AIDS (SB-728-T)
and NGF-AAV for Alzheimer's disease (CERE-110). Sangamo's other therapeutic
programs are focused on monogenic and rare diseases. The company has formed a
strategic collaboration with Shire International GmbH to develop therapeutics
for hemophilia, Huntington's disease and other monogenic diseases, and with
Biogen Idec for hemoglobinopathies, such as sickle cell disease and
beta-thalassemia. It has also established strategic partnerships with
companies in non-therapeutic applications of its technology, including Dow
AgroSciences and Sigma-Aldrich Corporation. For more information about
Sangamo, visit the Company's website at www.sangamo.com.
ZFP Therapeutic^® is a registered trademark of Sangamo BioSciences, Inc.
Logo - http://photos.prnewswire.com/prnh/20130102/SF35903LOGO
SOURCE Sangamo BioSciences, Inc.
Contact: Elizabeth Wolffe, Ph.D, 510-970-6000, x271, firstname.lastname@example.org; or
Varant Shirvanian, 510-970-6000, x205, email@example.com
Press spacebar to pause and continue. Press esc to stop.